The pharmaceutical firm did not specify the reason behind the extended review but said it expects the agency to issue its opinion in September.
Novartis also said that it still anticipates regulatory approval of the drug in Europe in Q2 of 2021.
Price: 85.50, Change: -0.96, Percent Change: -1.11
|Qualcomm Unit Invests $97 Million in Reliance Indust...|
|2020, and 2021 Estimates for Zynex Decreased but Q2 ...|
|2020 and 2021 Estimates for Zions Bancorporation Sca...|
|Joyy Inc's 2021 Earnings Forecast Raised|
|2020, 2021 Earnings Estimates for Cimarex Energy Raised|